Is Viagra the Next Longevity Drug? | Peter Koshland | Talk with Turek (Ep. 17)

When Pfizer's cardiac drug failed its trial for chest pain in the late 1990s, something unexpected happened. The men in the trial refused to return their pills. That accident became Viagra. Twenty-seven years later, the science has finally caught up to what those patients already knew, and the implications now reach well beyond sexual health. In Episode 17 of Talk with Turek, Dr. Paul Turek sits down with Peter Koshland, PharmD, CEO of Koshland Pharmacy and Assistant Clinical Professor at the UCSF School of Pharmacy, to unpack what the newest research is showing about PDE5 inhibitors (the drug class that includes sildenafil and tadalafil), and why an erection problem in a man's forties now carries a cardiovascular mortality risk roughly 2.2 times baseline. That is the same elevated risk as a smoking history. What this episode covers • The myths these medications have carried since 1998, including priapism, addiction, fertility harm, and eye damage, with the clinical reasoning behind each answer • What compounding pharmacy actually is, and why the FDA does not regulate compounded medications the way it regulates pharmaceutical-grade drugs • Why telehealth ED prescribing, while convenient, often misses the most important clinical conversation a man over 40 should be having • The triad of physician, pharmacist, and patient as the operating model for personalized care • How stress masquerades as organic erectile dysfunction, and the diagnostic dose-titration method Dr. Turek uses to tell the difference • Why the same erectile tissue exists in the nose, why these drugs cause nasal congestion, and what that reveals about how they work • The emerging science of female sexual dysfunction and how the conversation has shifted in the last 25 years Who this episode is for: • Men in their thirties asking the right questions early • Partners trying to understand what a prescription actually means • Physicians thinking about how to counsel patients differently in light of the new data • Anyone interested in longevity, preventive medicine, and the science of healthspan Peter Koshland, PharmD • CEO of Koshland Pharmacy • Assistant Clinical Professor of Pharmacy, University of California, San Francisco, School of Pharmacy • Chemistry degree from Georgetown University, PharmD from UCSF • Koshland Pharmacy specializes in compounded, customized medications with pharmaceutical- grade sourcing and clinical oversight • Website: koshlandpharm.com Connect With Us • Website: theturekclinic.com • Blog: turekonmenshealth.com • Book a consultation, in person or virtual: 888-887-3545 • Subscribe wherever you listen to podcasts and watch on YouTube at @TalkWithTurek Production Credit • Produced and recorded in South Pasadena, California, in association with Galaxy Media Ventures • Executive producers: Jennifer Harris and Rob Clyde • Episode produced by Max Flora • Engineered and edited by Drew Unser Disclaimer This podcast is for educational and informational purposes and is not a substitute for individualized medical advice. Please consult a qualified physician about your own health. #MensHealth #Viagra #longevity